AstraZeneca bolsters COVID therapeutics with RQ Bio deal ...Middle East

Devdiscourse - Opinion
AstraZeneca bolsters COVID therapeutics with RQ Bio deal
AstraZeneca is paying up to $157 million, plus royalties, for an exclusive licence to develop and sell a set of pre-clinical COVID antibody therapies developed by RQ Bio, the London-based biotech said on Tuesday.

Hence then, the article about astrazeneca bolsters covid therapeutics with rq bio deal was published today ( ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AstraZeneca bolsters COVID therapeutics with RQ Bio deal )

Apple Storegoogle play

Last updated :

Also on site :



Latest News